Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Alvarez-Larrán A, Garrote M, Ferrer-Marín F, Pérez-Encinas M, Mata-Vazquez MI, Bellosillo B, Arellano-Rodrigo E, Gómez M, García R, García-Gutiérrez V, Gasior M, Cuevas B, Angona A, Gómez-Casares MT, Martínez CM, Magro E, Ayala R, Del Orbe-Barreto R, Pérez-López R, Fox ML, Raya JM, Guerrero L, García-Hernández C, Caballero G, Murillo I, Xicoy B, Ramírez MJ, Carreño-Tarragona G, Hernández-Boluda JC, Pereira A; MPN Spanish Group (Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas).
Alvarez-Larrán A, et al. Among authors: del orbe barreto r.
Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. Epub 2022 Apr 13.
Cancer. 2022.
PMID: 35417564
Free PMC article.